#78 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
Clinicians need this review to understand the biological mechanisms by which cannabis affects mental health outcomes, enabling more informed risk-benefit discussions with patients considering or using cannabis. The evidence on cannabis and psychiatric conditions directly impacts clinical decision-making for patients with depression, anxiety, psychosis, and substance use disorders who may self-medicate or seek cannabis as treatment. Given increasing patient access through legalization, clinicians require this synthesized evidence to identify which populations face greatest mental health risks and provide appropriate screening and counseling.
This review examines the endocannabinoid system’s role in mental health and the clinical evidence for cannabis use in psychiatric conditions. The endocannabinoid system, consisting of receptors, endogenous ligands, and metabolic enzymes, plays an important role in mood regulation, anxiety processing, and stress response, suggesting a plausible biological mechanism for cannabis effects on mental health. However, the evidence for therapeutic benefit remains mixed, with some studies showing potential benefit for anxiety and PTSD while others demonstrate increased risk of psychosis, cognitive impairment, and worsening of mood disorders, particularly with high-THC products and in vulnerable populations. The review highlights a critical gap between patient interest in cannabis for psychiatric symptoms and the limited high-quality evidence supporting its use, alongside growing concerns about cannabis-induced psychiatric adverse effects. Clinicians should be aware that while the neurobiological rationale exists, current evidence does not support cannabis as a first-line treatment for most mental health conditions and that individual risk factors including genetic predisposition, age, and THC potency significantly influence outcomes. Patients seeking cannabis for anxiety, depression, or PTSD should have frank discussions with their physicians about limited efficacy evidence, documented harms, and the superiority of evidence-based psychiatric treatments.
“The endocannabinoid system’s role in mood regulation is real and measurable, but we have to be honest with our patients: cannabis as a psychiatric treatment remains empirical at best, and for people with genetic predisposition to psychosis or schizophrenia, the risks are substantial enough that I counsel against use regardless of symptom relief they might report.”
🧠 While the endocannabinoid system clearly plays important neurobiological roles in mood and stress regulation, the clinical translation of this mechanistic knowledge into cannabis use recommendations remains fraught with uncertainty. Current evidence suggests cannabis use, particularly in adolescence and in individuals with genetic vulnerability, may increase risk for psychotic disorders and worsen existing mood symptoms, yet the dose-response relationships, optimal cannabinoid ratios, and long-term safety profiles remain poorly characterized. Clinicians should recognize that patients often self-medicate with cannabis for anxiety and insomnia, creating a compelling narrative despite limited high-quality evidence for efficacy and clear harms in vulnerable populations. The heterogeneity of cannabis products, variable THC and CBD concentrations, and lack of standardized dosing further complicate any attempt to translate basic endocannabinoid science into clinical guidance. When counseling patients about cannabis use, providers should explicitly address the gap between
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: